Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors

Soft tissue sarcomas (STS) are aggressive tumors with a poor prognosis. Poly(ADP-ribose) polymerase (PARP)-1 inhibitors (PARPi) enhance the cytotoxic effects of radiation. In this study, we evaluated the effect of PARPi on survival and DNA damage of irradiated STS cells. For clonogenic assays, STS cell lines were irradiated with or without olaparib, iniparib or veliparib pretreatment. The effect of PARP inhibition on γ-H2AX and Rad51 foci formation, on PARP-1, phospho-ERK and cleaved caspase-3 protein expression and on cell cycle progression was evaluated on irradiated rhabdomyosarcoma cells pretreated with olaparib. The results from this work showed that PARPi induced significant radiosensitization in STS cells. Rhabdomyosarcoma cells showed the highest increase in radiosensitivity, with a radiosensitization enhancement ratio at 50% survival (ER50) of 3.41 with veliparib. All PARPi exerted a synergistic effect when combined with radiation. Fibrosarcoma cells showed an ER50 of 2.29 with olaparib. Leiomyosarcoma and liposarcoma cells showed their highest ER50 with veliparib (1.71 and 1.84, respectively). In rhabdomyosarcoma, olaparib enhanced the formation of radiation-induced γ-H2AX/Rad51 foci and PARP-1 cleavage, induced slightly increased expression of cleaved caspase-3 and reduced phospho-ERK expression. Moreover, the combination of olaparib and radiation resulted in a significantly enhanced cell cycle arrest in the G2/M phase compared to the two treatments alone. In conclusion, we have shown that PARPi are potent radiosensitizers of human STS cells. These results support the pursuit of further investigations into the effects of PARPi combined with radiation on STS.

[1]  B. Pasini,et al.  PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models , 2017, Molecular Cancer.

[2]  C. Lucchesi,et al.  Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas , 2017, Journal of Hematology & Oncology.

[3]  C. Pratilas,et al.  Targeted therapy for soft tissue sarcomas in adolescents and young adults , 2017, Adolescent health, medicine and therapeutics.

[4]  L. Livi,et al.  A PPAR-gamma agonist protects from radiation-induced intestinal toxicity , 2017, United European gastroenterology journal.

[5]  M. Khasraw,et al.  Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response? , 2017, Clinical and Translational Oncology.

[6]  R. Mairs,et al.  Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells , 2017, International journal of radiation biology.

[7]  I. Judson,et al.  UK guidelines for the management of soft tissue sarcomas , 2016, Clinical Sarcoma Research.

[8]  T. Galloway,et al.  The Role for Radiation Therapy in the Management of Sarcoma. , 2016, The Surgical clinics of North America.

[9]  L. Povirk,et al.  Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition , 2016, Radiation Research.

[10]  Iain J Hyndman,et al.  An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma , 2016, BMC Cancer.

[11]  Z. Cui,et al.  Knockdown of PARP-1 Inhibits Proliferation and ERK Signals, Increasing Drug Sensitivity in Osteosarcoma U2OS Cells , 2016, Oncology research.

[12]  T. Kondo,et al.  Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor , 2016, Genes to cells : devoted to molecular & cellular mechanisms.

[13]  D. Vanel,et al.  Translational research in diagnosis and management of soft tissue tumours , 2016, Cancer Imaging.

[14]  C. Ciccarelli,et al.  Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population , 2016, Molecular Cancer.

[15]  F. Engert,et al.  PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway , 2015, Molecular Cancer Therapeutics.

[16]  M. O’Connor,et al.  Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  T. Stokke,et al.  Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation , 2015, Cell cycle.

[18]  J. Mora,et al.  The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin , 2015, Oncotarget.

[19]  C. Scott,et al.  Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Jong-Soo Lee,et al.  Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer , 2015, BMC Cancer.

[21]  E. Deeks.  Olaparib: First Global Approval , 2015, Drugs.

[22]  G. Demetri,et al.  Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy , 2014, BMC Cancer.

[23]  E. Yang,et al.  An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. , 2014, Gynecologic oncology.

[24]  B. Telfer,et al.  Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft , 2011, Molecular Cancer Therapeutics.

[25]  F. Chibon,et al.  New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics , 2011, The Journal of pathology.

[26]  R. Bristow,et al.  Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. , 2010, Seminars in radiation oncology.

[27]  A. Chalmers,et al.  Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. , 2008, International journal of radiation oncology, biology, physics.

[28]  P. Metrakos,et al.  Mitogen-Activated Protein (MAP) Kinase/MAP Kinase Phosphatase Regulation: Roles in Cell Growth, Death, and Cancer , 2008, Pharmacological Reviews.

[29]  Linda J. Kuo,et al.  γ-H2AX - A Novel Biomarker for DNA Double-strand Breaks , 2008 .

[30]  M. Cohen-Armon.  PARP-1 activation in the ERK signaling pathway. , 2007, Trends in pharmacological sciences.

[31]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[32]  David H. Johnson,et al.  Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models , 2007, Clinical Cancer Research.

[33]  G. de Murcia,et al.  The PARP superfamily , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[34]  S. Jackson,et al.  Sensing and repairing DNA double-strand breaks. , 2002, Carcinogenesis.

[35]  Lewis C Cantley,et al.  PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.

[36]  D. Ward,et al.  Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Piccart,et al.  An update on PARP inhibitors—moving to the adjuvant setting , 2015, Nature Reviews Clinical Oncology.